

## Ceftolozane-Tazobactam (Zerbaxa®)

<b>SALAD – all Cephalosporins</b> cefAZOlin, cefOTAXime, cefTARoline, ceftAZidime, ceftRIAXone, cefuroxime, Ceftazidime – Avibactam (Zavicefta)										
<b>Contains a PENICILLIN-like structure</b> May be appropriate in penicillin-allergic patient. Refer to CUH Antimicrobial Guidelines on Eolas for further information before administration										
<b>Reserve Antimicrobial</b> See CUH Antimicrobial Guidelines on Eolas for further information										
<b>Form</b>	Vial contains ceftolozane 1g and tazobactam 500 mg. Prescribed as combination i.e. 1g/0.5g, 2g/1g etc	Store vials at 2–8°C in fridge								
<b>Reconstitution</b>	Add 10mL water for injections or sodium chloride 0.9% to each 1g ceftolozane/500mg tazobactam vial and shake gently. The final volume of each vial is approximately 11.4mL  <b>Dilute further prior to administration</b>									
<b>Compatibility &amp; Stability</b>	Sodium chloride 0.9% Glucose 5%									
<b>Administration</b>	<b>IV Infusion</b> <ul style="list-style-type: none"><li>Any required dose to 100ml infusion fluid</li><li>Administer over 60 minutes</li></ul> <table><tr><th>Dose of Ceftolazone/tazobactam</th><th>Volume of reconstituted solution</th></tr><tr><td>2g/1g</td><td>22.8ml (two vials)</td></tr><tr><td>1.5g/0.75g</td><td>17.1ml</td></tr><tr><td>1g/0.5g</td><td>11.4ml (one vial)</td></tr></table>		Dose of Ceftolazone/tazobactam	Volume of reconstituted solution	2g/1g	22.8ml (two vials)	1.5g/0.75g	17.1ml	1g/0.5g	11.4ml (one vial)
Dose of Ceftolazone/tazobactam	Volume of reconstituted solution									
2g/1g	22.8ml (two vials)									
1.5g/0.75g	17.1ml									
1g/0.5g	11.4ml (one vial)									
<b>Monitoring</b>	Monitor: Blood pressure, heart rate. Hypersensitivity reactions including anaphylaxis, nausea, abdominal pain headache, dizziness, anxiety, fever, hypotension, tachycardia, rash, infusion site reactions, dyspnoea.									
<b>Additional Information</b>	Manufacturer advises ceftolozane with tazobactam may influence driving and performance of skilled tasks—increased risk of dizziness.									

**Information provided relates to Zerbaxa® manufactured by Merck Sharp & Dohme**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*